Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

Çınar, Olgu Erkin; Sayınalp, Başak; Aladağ, Elifcan; Karataş, Ayşe Avşar; Velet, Mustafa; İnkaya, Ahmet Çağkan; Ortaç, Nazmiye Ebru Ersoy; Öcal, Serpil; Aksu, Salih; Haznedaroğlu, İbrahim C.; Sayınalp, Nilgün; Özcebe, Osman

doi:10.1016/j.transci.2020.102821

Cited by 45 publications

(44 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This needs careful interpretation due to a wide overall 95% CI as well as due to studies with different designs. This evidence is supported by two large cohort studies conducted in Spain and South Africa, showing that the risks for PCR-con rmed COVID-19 diagnosis, hospitalization, Intensive Care Unit (ICU) admission, and death among HIVpositive persons receiving ART were greater in men compared to old age [42][43][44][45][46][47][48]. However, the risk for hospitalization varied by the nucleoside transcriptase inhibitor (NRTI) regimen and was lower in patients receiving TDF/FTC versus those receiving other regimens [42][43][44][45][46][47][48].…”

Section: Discussionmentioning

confidence: 90%

“…Each article that met selection criteria was fundamentally assessed for Author/Country, Population/Study design, Exposures, Comparators, Treatments, TB occurrence and SARS/MERS/COVID-19 severity, recovery and mortality rate. [28][29][30][31], one case control study [32] and four case series [33][34][35][36] were conducted in China, two case series [37][38] were done in Singapore, one case series [39] and one case control study [40] were undertaken in Saudi Arabia, a case series [41] was conducted in Italy, one cohort study was done in South Africa [42] and another in the Philippines [43], one case study was conducted in the United State of America [44], other three case studies were found in Turkey [45], Hong Kong [46] and India [47] respectively.…”

Section: Search Resultsmentioning

confidence: 99%

“…SARS-CoV and HIV may decrease conjunctly CD4 count and lymphocytes, adding high corticosteroids [33] as a treatment for SARS-CoV may be TB precipitant factors [33]. Following this, SARS-CoV or COVID-19 patients may-be more susceptible to active and latent TB as proven by different studies [27,33,[44][45][46][47]. It is important to realize that lung lesions due to SARS and/or TB may increase signi cantly the likelihood of SARS-CoV and TB.…”

Section: Discussionmentioning

confidence: 99%

“…Eight out of fourteen had severe/critical disease course among which one case of SARS-CoV, one of MERS-CoV and six cases of COVID-19 and had a long recovery process. SARS-CoV or COVID-19 cases with PTB co-infection: Seven studies (an observational study, two case series and four case studies) [27,33,35,[44][45][46][47] diagnosed PTB (positive acid-fast bacilli smear on sputum samples or IGRA), while cases were admitted for SARS-CoV (two cases) and COVID-19 (twelve cases). SARS-CoV and COVID-19 were con rmed by RT-PCR, and microscopy as well as medical imaging diagnosed TB.…”

Section: Descriptive Analysismentioning

confidence: 99%

See 3 more Smart Citations

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Tamuzi

Birhanu

Shumba³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major global health challenges of the 21st century. In high burden HIV/TB countries, the spread of COVID-19 among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19 pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field. However, several gaps remain in the knowledge of the burden of COVID-19 on patients with TB and HIV. This study was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection or only TB, to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management.Methods: We conducted an electronic search of potentially eligible studies published in English in the Cochrane Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included case studies, case series and observational studies published between January, 2002 and July, 2020 in which SARS-CoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB in adults. We screened titles, abstracts and full articles for eligibility. Descriptive and meta-analysis were done and results have been presented in graphs and tables.Results: After removing 95 duplicates, 58 out of 437 articles were assessed for eligibility, of which 14 studies were included for descriptive analysis and seven studies were included in the meta-analysis. Compared to the descriptive analysis, the meta-analysis showed strong evidence that current TB exposure was high-risk COVID-19 group (OR 1.67, 95% CI 1.06-2.65, P= 0.03). The pooled of COVID-19/TB severity rate increased from OR 4.50 (95% CI 1.12-18.10, P=0.03), the recovery rate was high among COVID-19 compared to COVID-19/TB irrespective of HIV status (OR 2.23, 95% CI 1.83-2.74, P < 0.001) and the mortality was reduced among non-TB group (P<0.001).Conclusion: In summary, TB was a risk factor for COVID-19 both in terms of severity and mortality irrespective of HIV status. Structured diagnostic algorithms and clinical management are suggested to improve COVID-19/HIV/TB or COVID-19/TB co-infections outcomes.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Search Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Descriptive Analysismentioning

confidence: 99%

See 2 more Smart Citations

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Tamuzi

Birhanu

Shumba³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Search Resultsmentioning

confidence: 99%

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Tamuzi

Birhanu

Shumba³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major global health challenges of the 21 st century. In high burden HIV/TB countries, the spread of COVID-19 among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19 pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field and play an important role in the present and future management of the co-infections. However, several gaps are remaining in the knowledge of the burden of COVID-19 on patients with TB and HIV, the diagnosis, and management of these patients. Objectives The study was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection or only TB and to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management. Methods We conducted electronic search of potential eligible studies published in English in the Cochrane Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included case studies, case series and observational studies published between January, 2002 and March, 2020 in which SARS-CoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB were managed in adult patients. We screened titles, abstracts and full articles for eligibility. As we anticipated heterogeneity in the literature, results were reported narratively. Main results After removing 69 duplicates, 24 out of 246 articles were assessed for eligibility, of which 9 studies were included for qualitative analysis. Among them, we included two case reports, four case series, one case-control and two retrospective observational studies. The studies have shown that TB may occur during or after SARS-CoV. In terms of severity, the proportion of severe/critical SARS, MERS and COVID cases with TB co-infection was higher than in patients with mild/moderate stages (P= 0.0008). Conclusion SARS/MERS-CoV/COVID-19 associated to HIV/TB or TB subjects had a higher risk of developing severe/critical than mild/moderate SARS/MERS-CoV/COVID-19. Diagnostic algorithms and clinical management were suggested for efficiently improving COVID-19/HIV/TB co-infections outcomes.

show abstract

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

et al. 2023

View full text Add to dashboard Cite

ImportancePatients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to treat COVID-19, evolutions of SARS-CoV-2 have been associated with monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. Thus, the therapeutic use of COVID-19 convalescent plasma has increased on the presumption that such plasma contains potentially therapeutic antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient.ObjectiveTo assess the growing number of reports of clinical experiences of patients with COVID-19 who are immunocompromised and treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion.Data SourcesOn August 12, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma use in patients who are immunocompromised.Study SelectionRandomized clinical trials, matched cohort studies, and case report or series on COVID-19 convalescent plasma use in patients who are immunocompromised were included. The electronic search yielded 462 unique records, of which 199 were considered for full-text screening.Data Extraction and SynthesisThe study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 3 independent reviewers in duplicate and pooled.Main Outcomes and MeauresThe prespecified end point was all-cause mortality after COVID-19 convalescent plasma transfusion; exploratory subgroup analyses were performed based on putative factors associated with the potential mortality benefit of convalescent plasma.ResultsThis systematic review and meta-analysis included 3 randomized clinical trials enrolling 1487 participants and 5 controlled studies. Additionally, 125 case series or reports enrolling 265 participants and 13 uncontrolled large case series enrolling 358 participants were included. Separate meta-analyses, using models both stratified and pooled by study type (ie, randomized clinical trials and matched cohort studies), demonstrated that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for the amalgam of both randomized clinical trials and matched cohort studies (risk ratio [RR], 0.63 [95% CI, 0.50-0.79]).Conclusions and RelevanceThese findings suggest that transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have COVID-19.

show abstract

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

Cited by 45 publications

References 11 publications

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About